HC Wainwright Issues Pessimistic Outlook for MIST Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities researchers at HC Wainwright decreased their FY2028 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a research note issued to investors on Monday, March 17th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.43 per share for the year, down from their previous forecast of $0.46. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $1.81 EPS.

Milestone Pharmaceuticals Price Performance

Shares of Milestone Pharmaceuticals stock opened at $2.38 on Wednesday. The stock has a 50 day moving average price of $2.02 and a 200-day moving average price of $1.81. Milestone Pharmaceuticals has a one year low of $1.12 and a one year high of $2.75. The stock has a market cap of $126.92 million, a price-to-earnings ratio of -2.94 and a beta of 1.83. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in MIST. Jones Financial Companies Lllp raised its position in Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock worth $26,000 after purchasing an additional 10,000 shares during the period. National Bank of Canada FI raised its holdings in shares of Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock worth $44,000 after buying an additional 11,600 shares during the period. PVG Asset Management Corp purchased a new stake in shares of Milestone Pharmaceuticals in the third quarter worth approximately $46,000. Atria Investments Inc lifted its stake in shares of Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after acquiring an additional 12,430 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Milestone Pharmaceuticals during the 4th quarter valued at $73,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.